Kura Oncology Stock News

SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations Troy Wilson - President a

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Credit Suisse has raised the price target on Kura Oncology Inc (NASDAQ: KURA) to $29 from $27. The analysts say that evidence of an effective and tolerable agent and a clear recommended phase 2 d

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o

Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Troy Wilson – Chairman and Chief Executive Officer Tom Doyle – Senior Vice President

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA ), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022. "We look forward to showcasing the four abstracts for tipifarnib, including a late-breaking presentation highlighting the opportunity for our next-generation farnesyl transferase inhibitor program," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "We are excited about this emerging opportunity, focused on delaying the onset of drug resistance and look forward to sharing more detailed information at AACR next month. In the meantime, we intend to perform initial clinical evaluation with tipifarnib in non-small cell lung cancer while in parallel advancing KO-2806, the lead development candidate in our next-generation farnesyl transferase inhibitor program, through IND-enabling studies." Session titles and information for the four abstracts are listed below and are now available on the AACR online itinerary planner.

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Kura Oncology press release (KURA): Q4 GAAP EPS of -$0.49 beats by $0.05.Cash, cash equivalents and short-term investments totaled $518.0 million as of December 31, 2021, compared…

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2021 Results - Earnings Call Transcript

Kura Oncology (NASDAQ:KURA) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$0.54

Novartis AG with ticker code (NVS) now have 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 108 and 90 with the average target price sitting at 101.4. Given that the stocks previous close was at 87.94 this now indicates there is a potential upside of 15.3%. The day 50 moving average is 86.37 while the 200 day moving average is 87.38. The market cap for the company is $193,680m. Find out more information at: https://www.novartis.com [stock_market_widget type="chart" template="basic" color="green" assets=NVS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $223,324m based on the market concensus. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.